Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Prostatic Neoplasms 29Breast Neoplasms 28Brain Neoplasms 21Neoplasms 16Glioma 10Pancreatic Neoplasms 9Head and Neck Neoplasms 8Lymphoma 7Uterine Cervical Neoplasms 6Urinary Bladder Neoplasms 6Rectal Neoplasms 6Glioblastoma 6Colonic Neoplasms 6Carcinoma, Hepatocellular 6Lymphoma, Non-Hodgkin 5Lung Neoplasms 5Astrocytoma 5Triple Negative Breast Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Liver Neoplasms 4Disease 4Central Nervous System Neoplasms 4Stomach Neoplasms 3Spinal Cord Neoplasms 3Sarcoma 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Esophageal Neoplasms 3Carcinoma in Situ 3Retinoblastoma 2Pathologic Complete Response 2

Interventions

Cyclophosphamide 45Prednisone 31N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 29Vincristine 28Doxorubicin 27Etoposide 22romidepsin 20Gemcitabine 18Lenalidomide 1610-propargyl-10-deazaaminopterin 16fludarabine phosphate 15Whole-Body Irradiation 15Peripheral Blood Stem Cell Transplantation 14Brentuximab Vedotin 14Azacitidine 13Mycophenolic Acid 12Dexamethasone 10Cyclosporine 10Bortezomib 10Alemtuzumab 10Rituximab 8fludarabine 7belinostat 7Methotrexate 6Cytarabine 6Busulfan 6Bendamustine Hydrochloride 6pembrolizumab 5denileukin diftitox 5Nivolumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, T-Cell, Peripheral × Magnetic Resonance Imaging × Clear all
NCT04447027 2026-01-30

Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
26 enrolled 24 charts
DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡